Kurs
-2,53%
Likviditet
0,03 MSEK
Kalender
| Tid* | ||
| 2024-02-29 | - | Bokslutskommuniké 2023 |
| 2023-11-23 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-25 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-30 | - | Årsstämma |
| 2023-05-31 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-05 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
| 2023-02-28 | - | Bokslutskommuniké 2022 |
| 2023-02-09 | - | Extra Bolagsstämma 2022 |
| 2022-11-24 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-26 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-20 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
| 2022-05-19 | - | Årsstämma |
| 2022-05-11 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-25 | - | Bokslutskommuniké 2021 |
| 2021-11-12 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-16 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-17 | - | Årsstämma |
| 2021-05-27 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
| 2021-05-07 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-10 | - | Bokslutskommuniké 2020 |
| 2020-11-12 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-17 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-27 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
| 2020-05-26 | - | Årsstämma |
| 2020-05-15 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-14 | - | Bokslutskommuniké 2019 |
| 2019-11-15 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-19 | - | Extra Bolagsstämma 2019 |
| 2019-08-15 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-31 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
| 2019-05-29 | - | Årsstämma |
| 2019-05-15 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-28 | - | Bokslutskommuniké 2018 |
| 2018-11-30 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-31 | - | Kvartalsrapport 2018-Q2 |
| 2018-06-14 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
| 2018-06-13 | - | Årsstämma |
| 2018-05-31 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-28 | - | Bokslutskommuniké 2017 |
| 2017-11-28 | - | Kvartalsrapport 2017-Q3 |
| 2017-11-15 | - | Extra Bolagsstämma 2017 |
| 2017-08-31 | - | Kvartalsrapport 2017-Q2 |
| 2017-06-09 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
| 2017-06-08 | - | Årsstämma |
| 2017-05-31 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-20 | - | Bokslutskommuniké 2016 |
| 2016-11-30 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-31 | - | Kvartalsrapport 2016-Q2 |
| 2016-06-01 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
| 2016-05-31 | - | Årsstämma |
| 2016-05-31 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-29 | - | Bokslutskommuniké 2015 |
| 2016-01-21 | - | Extra Bolagsstämma 2016 |
| 2015-11-30 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-31 | - | Kvartalsrapport 2015-Q2 |
| 2015-06-12 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
| 2015-06-11 | - | Årsstämma |
| 2015-05-28 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-27 | - | Bokslutskommuniké 2014 |
| 2014-11-28 | - | Kvartalsrapport 2014-Q3 |
| 2014-09-12 | - | Extra Bolagsstämma 2014 |
| 2014-08-29 | - | Kvartalsrapport 2014-Q2 |
| 2014-06-10 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
| 2014-06-09 | - | Årsstämma |
| 2014-05-23 | - | Kvartalsrapport 2014-Q1 |
| 2014-03-05 | - | Bokslutskommuniké 2013 |
| 2013-11-29 | - | Kvartalsrapport 2013-Q3 |
| 2013-09-04 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-31 | - | Kvartalsrapport 2013-Q1 |
| 2013-05-08 | - | Split RLS 10:1 |
| 2013-04-11 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
| 2013-04-10 | - | Årsstämma |
| 2013-03-05 | - | Bokslutskommuniké 2012 |
| 2012-11-26 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-31 | - | Kvartalsrapport 2012-Q2 |
| 2012-06-12 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
| 2012-06-11 | - | Årsstämma |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
RLS Global's new clinical investigation with ChloraSolv for the treatment of pressure ulcers includes six clinics in Sweden, Finland and the UK. The first patient was enrolled on September 1 at a clinic in the UK.
The investigation has been approved by authorities in all three countries.
Pressure ulcers belong to the group of hard-to-heal wounds and cause much suffering and high costs worldwide. Studies show that pressure ulcers affect as many as over 10 (6-27) percent of all hospitalised patients in Europe (ref). Previous investigations have shown that ChloraSolv is effective and safe in the treatment of hard-to-heal leg ulcers and diabetic foot ulcers in need of debridement. This investigation is being carried out to extend the use of ChloraSolv and thus the opportunity to help even more patients.
Ref: Journal of Wound Care.2019 Nov 2;28(11):710-719 (https://www.magonlinelibrary.com/doi/abs/10.12968/jowc.2019.28.11.710)
THIS IS CHLORASOLV
ChloraSolv is a debriding gel, based on a unique hypochlorite technology, which is used with very good effect on leg ulcers and diabetic foot ulcers. The gel allows the gentle removal of devitalised tissue and promotes natural wound healing.[1]ChloraSolv does not damage healthy tissue and is well tolerated by the patient.
1. Eliasson, B., Fagerdahl, A.M., Jönsson, A., Apelqvist, J. Debriding effect of amino acid-buffered hypochlorite on hard-to-heal wounds covered by devitalized tissue: pilot study. Journal of Wound Care (June 2021) 30(6):455-464.
RLS Global's shares have been listed on the Nasdaq First North Growth Market since 17[th] May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag.
FOR MORE INFORMATION, PLEASE CONTACT:
Roland Frösing, acting CEO, RLS Global
E-mail: roland.frosing@rlsglobal.se (https://rls.global/investor/investor-relations-contact/roland.frosing@gmail.com)
Phone: +46 723 20 61 00